Amgen and AstraZeneca unveiled their first, direct-to-consumer U.S. advertising campaign in severe asthma called “Be You.” Launching ahead of Asthma & Allergy Awareness Month in May, the “Be You” campaign leverages visually distinct animated characters who do not let their disease define them. The campaign aims to raise awareness about a new severe asthma medicine called TEZSPIRE (tezepelumab-ekko).
Apotex Corp. announced April 12 the company’s release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane in the United States.
Boehringer Ingelheim Addresses Ukraine Crisis while Projecting 15 Launches by 2025Blockbusters, Boehringer Ingelheim, Breakthrough Therapy Designation, Business, Eli Lilly, Fibrotic Diseases, Financials, Idiopathic Pulmonary Fibrosis (IPF), Launches, Pharma Companies, Product Launches, Product Pipeline, Product Pipelines, Product Pipelines, Quarterly results, R&D, R&D Investment Return, Russia invasion, SGLT2 Inhibitors, Therapeutics, Ukraine
Boehringer Ingelheim announced the company’s intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
The U.S. Food and Drug Administration approved BioXcel Therapeutics Inc.’s IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Lumanity announced the acquisition of Innovative Edge (IE), a leading provider of pharmaceutical product launch services. IE partners with world-leading biopharma companies – from Top 20 pharmaceutical manufacturers to fast-growing biotechnology companies – to optimize and accelerate their global, regional, and local product launches.
Biosimilar development continues to advance for the U.S. market in anticipation of becoming an alternative to a brand drug with similar safety and efficacy.
Bristol Myers Squibb’s blockbuster cancer drug Revlimid finally has a competitor as Teva Pharmaceuticals announced the launch of a generic version of Revlimid, which could significantly cut into the global biopharmaceutical company’s earnings.
Peregrine Market Access, a leading life science commercialization partner, was selected by Nonagen Bioscience to become its contract commercialization organization for Oncuria. The breakthrough bladder cancer diagnostic test Oncuria is being developed to aid in detection, therapy choice, and disease monitoring. Under a multiyear, multimillion dollar agreement, Peregrine Market Access will lead the U.S. launch of Oncuria.
Dr. Reddy’s Laboratories Ltd. along with the company’s subsidiaries announced that Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide) capsules, was approved by Health Canada and launched in the Canadian market.
Dr. Reddy’s Laboratories Ltd. announced that the first consignment of imported doses of the Sputnik V vaccine that landed in India on May 1, 2021, received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13, 2021.